Clinical trial results of Zytiga, a new drug from Johnson & Johnson, showed incredible promise in the fight of prostate cancer. Shortly after the findings were presented at the year’s biggest cancer conference, a statistician raised concerns that the clinical trial had been stopped prematurely, which gave the impression the drug was more effective than it is. Helping to decide when clinical trials should stop or continue are data safety monitoring boards. DSMBs watch for emerging side effects, evidence that the drug does not work, or that the drug is so effective that it is no longer ethical to give patients a placebo. Statisticians are concerned over a recent trend by DSMBs to stop trials early. There’ve been times when stopped-early studies proved the benefits of several new drugs, but, in the case of Zytiga, the results were not far more statistically significant than normal.
The Illinois carrier recently raised $35 million through a stock offering.
One of the recorded votes on amendments was on a jab at short-term health insurance.
The policy will offer the insureds access to the SilverSneakers and WholeHealth Living Choices programs.
Sponsored by Fidelity Investments
Get insights into the mindset that’s driving today’s advisors to make a move--and help realize their unique business vision.
Don’t miss crucial news and insights you need to make informed investment advisory decisions. Join ThinkAdvisor.com now!
- Free unlimited access to ThinkAdvisor.com which provides advisors, like you, with comprehensive coverage of the products, services and trends necessary to guide your clients in making critical wealth, health and life decisions.
- Exclusive discounts on ALM and ThinkAdvisor events.
- Access to other award-winning ALM websites including TreasuryandRisk.com and Law.com.
Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.